Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Systematic Financial Management LP

Systematic Financial Management LP grew its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 396,877 shares of the specialty pharmaceutical company’s stock after buying an additional 2,536 shares during the quarter. Jazz Pharmaceuticals accounts for 1.6% of Systematic Financial Management LP’s holdings, making the stock its 5th largest holding. Systematic Financial Management LP owned approximately 0.65% of Jazz Pharmaceuticals worth $67,469,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in shares of Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after buying an additional 298,815 shares in the last quarter. Capital World Investors grew its stake in shares of Jazz Pharmaceuticals by 0.4% in the third quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company’s stock valued at $336,731,000 after buying an additional 10,345 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Jazz Pharmaceuticals by 11.4% in the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after buying an additional 191,637 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after buying an additional 145,865 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at $127,344,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Norbert G. Riedel sold 3,415 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the completion of the transaction, the director directly owned 7,024 shares of the company’s stock, valued at approximately $1,348,608. This represents a 32.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $194.49, for a total value of $1,039,160.07. Following the transaction, the senior vice president directly owned 28,728 shares of the company’s stock, valued at approximately $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 74,015 shares of company stock worth $14,180,486. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.2%

NASDAQ:JAZZ opened at $239.83 on Friday. The stock has a 50-day simple moving average of $202.44 and a 200-day simple moving average of $179.99. The stock has a market cap of $15.05 billion, a P/E ratio of -11,985.51, a P/E/G ratio of 0.43 and a beta of 0.27. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $243.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The business had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $188.00 to $307.00 in a research note on Tuesday. Morgan Stanley reissued an “overweight” rating and set a $245.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Leerink Partners boosted their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. TD Cowen boosted their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Piper Sandler boosted their target price on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.53.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.